Here we tested the ability of HGF to rescue cells from dabrafenib, a selective BRAF inhibitor, approved for the treatment of BRAFV600E mutant melanoma, with similar clinical efficacy as vemurafenib but a differentiated safety profile. This evidence concerns the gene HGF and melanoma.